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Abstract
Introduction—Over time there has been substantial improvement in antiretroviral treatment 
(ART) programmes, including expansion of services and increased patient engagement. We 
describe time trends in, and factors associated with, loss to follow-up (LTFU) in HIV-positive 
patients receiving ART in Asia.
Methods—Analysis included HIV-positive adults initiating ART in 2003-2013 at seven ART 
programmes in Asia. Patients LTFU had not attended the clinic for ≥180 days, had not died or 
transferred to another clinic. Patients were censored at recent clinic visit, follow-up to January 
2014. We used cumulative incidence to compare LTFU and mortality between years of ART 
initiation. Factors associated with LTFU were evaluated using a competing risks regression model, 
adjusted for clinical site.
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Results—A total of 8,305 patients were included. There were 743 patients LTFU and 352 deaths 
over 26,217 person-years (pys), a crude LTFU and mortality rate of 2.83 (2.64-3.05) per 100 pys 
and 1.34 (1.21-1.49) per 100 pys, respectively. At 24 months, the cumulative LTFU incidence 
increased from 4.3%(2.9-6.1%) in 2003-05 to 8.1%(7.1-9.2%) in 2006-09, then decreased to 
6.7%(5.9-7.5%) in 2010-13. Concurrently, the cumulative mortality incidence decreased from 
6.2%(4.5-8.2%) in 2003-05 to 3.3%(2.8-3.9%) in 2010-13. The risk of LTFU reduced in 2010-13 
compared to 2006-09 (adjusted subhazard ratio=0.73, 0.69-0.99).
Conclusions—LTFU rates in HIV-positive patients receiving ART in our clinical sites have 
varied by the year of ART initiation, with rates declining in recent years while mortality rates have 
remained stable. Further increases in site-level resources are likely to contribute to additional 
reductions in LTFU for patients initiating in subsequent years.
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Introduction
The expansion of antiretroviral treatment (ART) has had substantial impact on the outcomes 
of HIV-positive patients. However, HIV care requires lifelong ART which causes a 
considerable burden on ART programmes to retain patients in-care. Many ART programmes 
and cohort studies have shown large numbers of patients lost to follow-up (LTFU) following 
ART initiation. Studies in Sub-Saharan Africa have reported high rates of LTFU within 6 
months following ART initiation1. More than half the patients receiving ART in two care 
and treatment centres in Tanzania were LTFU within 3 months of ART initiation2. While a 
systematic review of patient retention in sub-Saharan Africa after ART initiation found that 
LTFU exceeded death as the cause of patient attrition (59% vs 41%)3.
In addition, there are significant clinical implications for patients who are LTFU. Patients 
who are LTFU often have high mortality rates, particularly from low-income countries4-8. 
Unreported deaths in LTFU patients can also bias findings from analyses, particularly in 
time-to-event analyses9,10. There is also a risk that LTFU patients will discontinue or 
interrupt ART. One study in Malawi reported that of the 2 183 LTFU patients who had 
initiated ART, 1 250 (57.3%) had either stopped or interrupted ART after being LTFU11. 
These treatment interruptions are concerning as they may lead to viral rebound and an 
increased chance of HIV transmission and drug resistance12. CD4 cell count restoration and 
overall prognosis are also hindered during periods of ART interruption13-15. Hence, there is 
a strong need to retain patients in care to achieve better patient outcomes and reduce the 
transmission of HIV through sustained viral suppression.
There have been substantial improvements in ART programmes globally to retain HIV-
positive patients in long-term care16,17. Previous studies have highlighted that the use of 
support services offered by HIV programmes is associated with increased engagement in-
case18,19. The HIV cascade of care describes how patients move between stages of care, 
from HIV diagnosis, to linkage and retention in care, to ART initiation and viral load 
suppression20. The cascade of care highlights the importance of all stages of HIV care and, 
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ideally, 90% or more of patients will achieve each stage21. However, disparities in the 
continuum of care do occur and, as ART scale-up continues, there may be an increased 
proportion of patients LTFU22. As patients receiving ART continue to increase, HIV 
programmes have a limited capacity to maintain the quality of care provided and retention in 
long-term care becomes more challenging23. Over the past decade, treatment coverage in 
Asia has substantially increased from 19% in 2010 to 41% in 2015, with an estimated 2.1 
million people receiving ART16. Yet, Asia is a diverse region with the HIV epidemic 
considered as concentrated in particular high risk populations and countries including India 
and Cambodia24. Monitoring patient retention rates in Asia is important to ensure the long-
term success of HIV treatment services in the region. Our study objective was to analyse and 
describe time trends in and factors associated with LTFU in HIV-positive patients receiving 
ART in Asia.
Methods
Data collection and Participants
We used observational patient data collected in the TREAT Asia HIV Observational 
database Low Intensity TransfEr (TAHOD-LITE), a sub-study of the TREAT Asia HIV 
Observational database (TAHOD), member cohorts of the International Epidemiology 
Databases to Evaluate AIDs (IeDEA)25. Currently, TAHOD collects prospective data on a 
subset of patients attending 20 treatment sites in Asia and TAHOD-LITE collects 
retrospective data on all patients seen at 8 of the 20 treatment sites, including one each in 
Cambodia, Hong Kong, India, Indonesia, Singapore, and South Korea, and two in Vietnam. 
A more detailed description of TAHOD-LITE has been previously described26. Briefly, 
routine patient data collected at the treatment site are anonymized and then electronically 
transferred for data management and analysis at the Kirby Institute, UNSW Australia. 
Patient data are limited to demographics, hepatitis serology, ART history and HIV-related 
laboratory results. TAHOD-LITE was granted ethics approvals from Institutional Review 
Boards (IRB) at each participating site, the University of New South Wales and the 
coordinating center at TREAT Asia/amfAR.
This analysis was limited to only 7 of the 8 sites that were able to distinguish LTFU from 
patient transfers to another clinical site for ongoing care. Hence, patient data were used from 
7 sites representing 6 countries in Asia. Patients were eligible for inclusion if aged over 18 
years, they had initiated an ART regimen consisting of three or more antiretroviral drugs 
from 01 January 2003 to 31 December 2013, and they had at least one subsequent follow-up 
visit after ART initiation.
Statistical analyses
Patients were defined as LTFU if they had not attended the clinic for at least 180 days and 
had not been transferred to another clinic or died. Sites determined whether patients had 
transferred to another clinic, either through clinic referral or self-referral to another clinic. 
Sites conducted their own patient tracing methods, according to local standards of practice, 
to identify patients who missed appointments and attempt to re-engage them into care or 
identify if they had been transferred to another clinic. No additional post-LTFU patient 
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tracing was conducted as part of this study. The 180 day cut-off was selected as this has 
previously been validated in our cohort to achieve the highest sensitivity and specificity for 
determining LTFU patients27,28. Re-engagement into care after the first LTFU event was not 
considered. Hence, once patients were LTFU, subsequent follow-up was not included in the 
analysis. Follow-up was from the start of ART initiation to the date of death or most recent 
clinic visit, whichever occurred first. Patient follow-up was censored at 01 January 2014. We 
used a quasi intention-to-treat approach where changes to treatment after ART initiation 
were ignored.
Pre-ART laboratory results were defined as the result closest to and within 6 months prior to 
ART initiation. Patients were censored at most recent clinic visit and death was considered 
as a competing event. We used the observed cumulative incidence of LTFU to compare 
between year periods of ART initiation. Fine and Gray methods 29 for competing risks 
regression models were used to evaluate factors associated with LTFU, adjusted by clinical 
site. Covariates selected a priori only included age at ART initiation, sex, mode of HIV 
exposure, time-updated CD4 cell count (cells/μL), time-updated HIV viral load (copies/mL), 
first ART regimen, hepatitis B (HBV) and hepatitis C co-infection (HCV).
Data were analysed using Stata version 14 (Stata Corporation, College Station, Texas, USA) 
and SAS software (Version 9.4 for Windows).
Results
A total of 8 382 patients from the seven eligible sites were aged over 18 years and had 
initiated ART between 1 January 2003 and 31 December 2013. Of these, 77 patients (0.9%) 
were excluded as they did not have subsequent visits after ART initiation. The remaining 8 
305 patients were included in our analysis.
Patient Characteristics
Overall, patients were male (69%), initiated ART in more recent year periods (2003-05: 9%; 
2006-09: 33%; 2010-13: 58%) and had heterosexual contact as their reported mode of HIV 
exposure (66%). The median age was 35 years (interquartile range [IQR]: 30-44). The 
majority of patients had been tested at least once for HBV and HCV, and 9% and 12%, 
respectively, had ever tested positive. The median pre-ART CD4 cell count and pre-ART 
HIV viral load was 117 cells/μL (IQR: 32-239) and 105 000 copies/mL (IQR: 30 589-358 
000), respectively. Most patients did not have previous mono/dual therapy (98%) and had 
initiated an ART regimen consisting of nucleoside reverse transcriptase inhibitors (NRTIs) 
and non-nucleoside reverse transcriptase inhibitor (NNRTI) (92%). The largest proportion of 
patients were from Cambodia (30%), followed by Singapore (22%), Vietnam (19%), 
Indonesia (13%), Hong Kong (10%) and South Korea (6%) (Table 1).
Cumulative LTFU and mortality rates
The median duration of follow-up was 34 months (IQR: 15-62 months). Of the 8 305 
patients, 743 patients were LTFU over 26 217 person-years (pys), giving a crude LTFU rate 
of 2.83 (95% CI: 2.64-3.05) per 100 pys (Table 2). In addition, there were 352 deaths with a 
crude death rate of 1.34 (95% CI: 1.21-1.49) per 100 pys.
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The cumulative LTFU incidence at 6, 12 and 24 months of follow-up for patients initiating 
ART: in 2003-05 was 1.5% (95% CI: 0.8-2.8%), 2.8% (95% CI: 1.7-4.4%) and 4.3% (95% 
CI: 2.9-6.1%); in 2006-09 was 2.9% (95% CI: 2.3-3.6%), 4.9% (95% CI: 4.2-5.8%) and 
8.1% (95% CI: 7.1-9.2%); in 2010-13 was 2.1% (95% CI: 1.7-2.5%), 4.0% (95% CI: 
3.4-4.6%) and 6.7% (95% CI: 5.9-7.5%), respectively (Figure 1).
The cumulative mortality incidence at 6, 12 and 24 months of follow-up for patients 
initiating ART: in 2003-05 was 2.7% (95% CI: 1.6-4.2%), 4.3% (95% CI: 2.9-6.0%) and 
6.2% (95% CI: 4.5-8.2%); in 2006-09 was 2.1% (95% CI: 1.6-2.8%), 2.6% (95% CI: 
2.1-3.3) and 3.4% (95% CI: 2.8-4.1%); in 2010-13 was 2.0% (95% CI: 1.6-2.4%), 2.7% 
(95% CI: 2.3-3.3%) and 3.3% (95% CI: 2.8-3.9%), respectively (Figure 1).
The cumulative LTFU and mortality incidence has also been shown by country (Appendix 
1). Three of the six countries displayed similar trends to the overall results, where the 
cumulative incidence of LTFU was high and mortality was low during 2006-09. However, 
the cumulative LTFU incidence reduction was less pronounced or even higher in 2010-13. 
Two of the six countries had consistent mortality and LTFU cumulative incidence during all 
time periods. One of the six countries only had data available for one time period (2010-13).
Factors associated with LTFU
The multivariate competing risks regression model, adjusted by clinical site, suggested that 
LTFU was associated with year of ART initiation, when adjusting for other relevant 
covariates (Table 2). Patients initiating in 2003-05 and 2010-13 had a subhazard ratio (SHR) 
of 0.73 (95% CI: 0.56-0.95; p value=0.021) and 0.83 (95% CI: 0.69-0.99; p value=0.034), 
respectively, compared to those initiating in 2006-09, adjusting for clinical site and other 
covariates.
Age at ART initiation was also significant in the multivariate model (p value=0.003), where 
those who were aged above 50 years were 31% less likely to be LTFU compared to those 
aged 30 or below (SHR: 0.69, 95% CI: 0.53-0.90, p value=0.007). Patients with homosexual 
contact or injecting drug use as the mode of HIV exposure were 36% (SHR: 1.36, 95% CI: 
1.05-1.76, p value=0.021) and 65% (SHR: 1.65, 95% CI: 1.19-2.30, p value=0.003) more 
likely to be LTFU compared to patients with heterosexual contact, respectively.
Patients with a higher current CD4 cell count were also less likely to be LTFU (p value 
<0.001). Those with a current CD4 count above 200 cells/μL were 67% less like to be LTFU 
compared to those with a current CD4 cell count ≤50 cells/μL (SHR: 0.32, 95% CI: 
0.25-0.41, p value<0.001). Patients ever having a positive HCV antibody test were 54% 
more likely to be LTFU than those that had never contracted HCV (SHR: 1.54, 95% CI: 
1.16-2.05, p value=0.003). Clinical site was significantly associated with LTFU in the 
multivariate model (p value <0.001). The two larger sites, Cambodia and Singapore, had a 
higher risk of LTFU compared to the other sites.
De La Mata et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
Our findings have shown that the rate of LTFU has varied by year of ART initiation in this 
cohort of 8 305 HIV-positive patients receiving ART in Asia. The LTFU rate was lowest for 
those initiating in 2003-05, reaching 4.3% at 24 months of follow-up. The mortality rate was 
highest during this period of ART initiation, with a cumulative incidence of 6.2% at 24 
months of follow-up. However, in 2006-09, there was a rapid increase in the LTFU rate to 
8.1% at 24 months of follow-up while the mortality rate nearly halved to 3.4% at 24 months 
of follow-up. During 2010-13, the LTFU rate decreased compared to the previous period to 
6.7% at 24 months of follow-up, while the mortality rate remained stable at 3.3% at 24 
months of follow-up. The mortality rate surpassed LTFU rates only during the first 4 months 
of follow-up for those initiating ART in 2006-09 and 2010-13.
Since the UNAIDS initiative to scale-up universal access to ART, there has been a 
substantial increase in the expansion of services and HIV-positive people receiving ART in 
Asia as well as other regions 30-32. Significant improvements in the survival of patients 
receiving ART followed, likely as a result of a combination of factors including greater 
access to ART, earlier initiation of ART and, more tolerable and convenient ART 
regimens26. However, the rapid growth within the programs may also be accompanied by 
poorer patient retention and higher rates of LTFU33. There was some indication in our 
findings to suggest that sites with more patients tended to have higher LTFU rates than other 
sites. Recently, there has been greater attention on reducing LTFU rates to ensure patients 
are retained in care, maintain adherence and achieve better long term outcomes5,34. 
Treatment programmes in Asia commonly conduct at least one form of outreach and 
tracking for adults receiving ART who have missed clinic visits19. Most report phone call as 
the method of contact, but other methods include sending letters, home visits, consulting 
with pharmacies and checking hospital records. ART adherence support services, such as 
one-on-one counselling and reminder tools, are also offered at a vast majority of treatment 
programmes. Hence, increased support services and other resources at the site-level to 
engage patients in long-term care may have contributed to the decreasing LTFU seen in 
recent years35.
Similar trends have been reported in a multiregional analysis where the LTFU rate at 12 
months after ART initiation increased from 9.3 per 100 pys (95% CI: 8.7-9.9) in 2004 to 
14.6 per 100 pys (95% CI: 14.1-15.2) in 2010 36. Concurrently, the mortality rate at 12 
months from ART initiation decreased from 11.8 per 100 pys (95% CI: 11.1-12.6) to 5.1 per 
100 pys (95% CI: 4.8-5.4) in 2010. Other studies have reported a less prominent increase in 
LTFU rates after scale-up37. Our cumulative LTFU incidence ranged between 4.3-8.1% at 24 
months, depending on year of ART initiation. This was relatively low compared to other 
HIV cohorts within the region which may be reflective of our ART programmes generally 
being better resourced tertiary referral sites. The LTFU incidence in India and China was 
14% and 16%, at 24 months, for patients initiating ART in 2007-11 and 2005-10, 
respectively38,39. Outside of the region, in Rwanda, the cumulative LTFU rate for patients 
initiating ART in 2005-10 was low at 4.4% (95% CI: 4.4-4.5%) at 24 months. However, the 
cumulative mortality rate was nearly double our mortality rate at 6.3% (95% CI: 
6.2-6.4%) 40. While in South Africa, both LTFU and mortality rates are much higher at 24 
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months, ranging from 13.4% (95% CI: 12.0-14.9%) to 26.5% (95% CI: 23.8-29.2%) and 
7.4% (95% CI: 6.4-8.5%) to 15.4% (95% CI: 13.2-17.6%), respectively, for patients 
initiating in 2005-2010 at three different HIV programmes41.
Our findings also highlight that lower CD4 count is strongly associated with a greater risk of 
LTFU. Previous studies have also shown a similar association42-44. As LTFU patients have a 
high mortality rate, the lower CD4 count may reflect the association with mortality arising 
from unreported deaths rather than LTFU from a lack of engagement in care. It may also 
relate to suboptimal adherence, where those patients less engaged with care also have lower 
ART adherence, leading to lower CD4 counts and subsequently LTFU45,46.
The risk of LTFU was highest among those aged ≤30 years at ART initiation. This is 
consistent with Africa cohorts where retention in care is lowest among the ≤30 age group 
and highlights the need to engage adolescents and young adults47. In contrast with European 
and US HIV studies, we did not see greater retention in those aged >50 years at ART 
initiation48. Patients with HCV co-infection, homosexual contact or injecting drug use as the 
mode of HIV exposure were associated with a higher risk of LTFU. These populations are 
often marginalized and faced with stigma and discrimination, subsequently impacting on 
their engagement with health services49-52.
There were limitations to our study. Some patient data had large proportions of missing data, 
such as HIV viral load. Subsequently, the association with LTFU should not be over 
interpreted. In addition, while our study had a relatively large patient sample size, our data 
was obtained from seven clinical sites across six countries from Asia, where most countries 
had one contributing site. Hence, our analysis is not necessarily representative of trends 
occurring within the given country or the region. There is also the potential for site-level 
differences in the resources available that can dictate the level of patient care provided, the 
type of ART and other unmeasurable confounders that could influence the results. 
Disengagement from the clinic may be influenced by cultural or social factors that vary 
between the countries, such as stigma and discrimination53. Hence, it is difficult to make 
direct comparisons of LTFU between our clinical sites. However, we have adjusted for 
clinical site in the multivariate model, as well as providing figures by clinical site, to account 
for heterogeneity between the sites and produce more reliable estimates.
Another limitation is the bias arising from our chosen LTFU definition27. Previous studies 
have used definitions ranging from 90 days 7 to 365 days 54 with no clinic visit. We have 
attempted to minimize error in the determining patients LTFU by using validated definitions 
that achieve optimal specificity and sensitivity for LTFU, both in our own TAHOD cohort28 
and supported by other studies55. Transient gaps between clinical visits can also introduce 
bias in identifying LTFU patients who have recently initiated ART. As patients who initiate 
ART recently have less time to return to care, they are more likely to be incorrectly 
classified as LTFU following a temporary interruption in care. However, this tends to 
overestimate LTFU rates in patients with recent ART initiation56. Therefore, our observed 
LTFU rates are likely to be conservative of the true LTFU rate and there is potentially a 
greater difference between the LTFU rates in 2006-09 and 2010-13.
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Patient deaths were ascertained through hospital records and, in some cases, through further 
tracing to national death registries or verbal autopsy, but this was site dependent and 
practices may have varied over time. Hence, there is possible bias in the underreporting of 
deaths, where some patients may have been incorrectly classified as LTFU. In particular, the 
increasing number of patients presenting for care may have contributed to under-recording 
of deaths in recent years. However, our mortality rate was consistent between 2006-09 and 
2010-13, and our observed LTFU rate could be overestimating the true LTFU and 
underestimating mortality rates.
In conclusion, we have shown that the LTFU rates in HIV-positive patients receiving 
antiretroviral therapy in our cohort have varied by the year of ART initiation. With an 
increasing number of patients initiating ART, the mortality rate in 2003-05 halved in 
subsequent years while the LTFU rate markedly increased. Those initiating in 2010-13 have 
reduced LTFU rates compared to 2006-09, while maintaining the same low mortality rate. 
Further increases in site-level resources to improve adherence counselling and support 
services would be needed to reduce LTFU and promote retention as HIV care increasingly 
transitions to a chronic disease management model35,57,58.
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Figure 1. Cumulative incidence of LTFU and death across all countries, by year of ART initiation
De La Mata et al. Page 12
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
De La Mata et al. Page 13
Ta
bl
e 
1
Su
m
m
ar
y 
of
 th
e p
at
ie
nt
 ch
ar
ac
te
ri
st
ic
s a
cr
o
ss
 a
ll 
co
un
tr
ie
s
LT
FU
In
 c
ar
e
D
ea
th
s
A
ll 
pa
tie
nt
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
To
ta
l
74
3
72
10
35
2
83
05
(10
0)
Ye
a
r 
o
f A
RT
 in
iti
at
io
n
 
20
03
-0
5
67
(9)
56
4
(8)
75
(21
)
70
6
(9)
 
20
06
-0
9
39
6
(53
)
22
40
(31
)
12
4
(35
)
27
60
(33
)
 
20
10
-1
3
28
0
(38
)
44
06
(61
)
15
3
(43
)
48
39
(58
)
A
ge
 
≤3
0
24
5
(33
)
19
86
(28
)
69
(20
)
23
00
(28
)
 
31
-4
0
25
5
(34
)
29
50
(41
)
13
1
(37
)
33
36
(40
)
 
41
-5
0
15
0
(20
)
13
99
(19
)
68
(19
)
16
17
(19
)
 
51
+
93
(13
)
87
5
(12
)
84
(24
)
10
52
(13
)
 
M
ed
ia
n 
[IQ
R]
35
[2
9, 
44
]
35
[3
0, 
43
]
39
[3
2, 
50
]
35
[3
0, 
44
]
Se
x
 
M
al
e
50
3
(68
)
49
29
(68
)
28
0
(80
)
57
12
(69
)
 
Fe
m
al
e
24
0
(32
)
22
76
(32
)
69
(20
)
25
85
(31
)
 
Tr
an
sg
en
de
r
0
(-)
5
(0)
3
(1)
8
(<
0.2
)
M
od
e 
of
 H
IV
 ex
po
su
re
 
H
et
er
os
ex
u
al
50
3
(68
)
48
05
(67
)
21
3
(61
)
55
21
(66
)
 
H
om
os
ex
u
al
 c
on
ta
ct
10
6
(14
)
11
13
(15
)
34
(10
)
12
53
(15
)
 
In
jec
tin
g d
rug
 us
er
65
(9)
58
4
(8)
66
(19
)
71
5
(9)
 
O
th
er
/U
nk
no
w
n
69
(9)
70
8
(10
)
39
(11
)
81
6
(10
)
H
C
V
 (e
v
er
)
 
N
eg
at
iv
e
49
9
(67
)
53
87
(75
)
23
7
(67
)
61
23
(74
)
 
Po
sit
iv
e
73
(10
)
81
9
(11
)
68
(19
)
96
0
(12
)
 
N
ot
 te
ste
d
17
1
(23
)
10
04
(14
)
47
(13
)
12
22
(15
)
H
BV
 (e
v
er
)
 
N
eg
at
iv
e
51
9
(70
)
56
34
(78
)
27
1
(77
)
64
24
(77
)
 
Po
sit
iv
e
59
(8)
63
4
(9)
40
(11
)
73
3
(9)
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
De La Mata et al. Page 14
LT
FU
In
 c
ar
e
D
ea
th
s
A
ll 
pa
tie
nt
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
 
N
ot
 te
ste
d
16
5
(22
)
94
2
(13
)
41
(12
)
11
48
(14
)
Pr
e-
A
RT
 C
D
4 
(ce
lls
/μL
)
 
≤5
0
23
9
(32
)
21
04
(29
)
17
4
(49
)
25
17
(30
)
 
51
-1
00
10
0
(13
)
83
9
(12
)
74
(21
)
10
13
(12
)
 
10
1-
20
0
15
4
(21
)
12
95
(18
)
48
(14
)
14
97
(18
)
 
>
20
0
19
4
(26
)
23
16
(32
)
29
(8)
25
39
(31
)
 
N
ot
 te
ste
d
56
(8)
65
6
(9)
27
(8)
73
9
(9)
 
M
ed
ia
n 
[IQ
R]
10
8
[3
0, 
21
7]
12
6
[3
4, 
24
6]
45
[1
6, 
97
]
11
7
[3
2, 
23
9]
Pr
e-
A
RT
 v
ir
al
 lo
ad
 (c
op
ies
/m
L)
 
≤1
0ˆ
5
75
(10
)
11
38
(16
)
42
(12
)
12
55
(15
)
 
>
10
ˆ5
56
(8)
11
77
(16
)
67
(19
)
13
00
(16
)
 
N
ot
 te
ste
d
61
2
(82
)
48
95
(68
)
24
3
(69
)
57
50
(69
)
 
M
ed
ia
n 
[IQ
R]
62
00
0
[2
03
03
,26
40
00
]
10
5 
00
0
[3
0 5
00
,36
2 4
00
]
15
1 
90
0
[7
0 5
00
,38
0 8
40
]
10
50
00
[3
05
89
,35
80
00
]
Fi
rs
t A
RT
 re
gi
m
en
 
N
RT
I+
N
N
RT
I
70
0
(94
)
66
18
(92
)
31
3
(89
)
76
31
(92
)
 
N
RT
I+
PI
41
(6)
50
5
(7)
37
(11
)
58
3
(7)
 
O
th
er
2
(0)
87
(1)
2
(1)
91
(1)
Pr
ev
io
us
 m
on
o/
du
al
 th
er
ap
y
 
N
o
72
8
(98
)
70
61
(98
)
32
9
(93
)
81
18
(98
)
 
Ye
s
15
(2)
14
9
(2)
23
(7)
18
7
(2)
C
lin
ic
al
 S
ite
 
Ca
m
bo
di
a
32
3
(44
)
21
15
(29
)
97
(28
)
25
35
(30
)
 
H
on
g 
K
o
n
g
14
(2)
70
4
(10
)
76
(22
)
79
4
(10
)
 
In
do
ne
sia
11
4
(15
)
95
4
(13
)
29
(8)
10
97
(13
)
 
Si
ng
ap
or
e
22
2
(30
)
15
29
(21
)
50
(14
)
18
01
(22
)
 
Vi
et
na
m
33
(4)
14
67
(21
)
92
(26
)
15
92
(19
)
 
So
ut
h 
Ko
re
a
37
(5)
44
1
(6)
8
(2)
48
6
(6)
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
De La Mata et al. Page 15
Ta
bl
e 
2
Fa
ct
or
s a
ss
oc
ia
te
d 
w
ith
 p
er
m
an
en
t L
TF
U,
 d
ef
in
ed
 a
s n
o 
cl
in
ic
 v
isi
t f
o
r 
18
0 
da
ys
, a
m
on
g 
al
l p
at
ie
nt
s u
nd
er
 fo
llo
w
-u
p
Ev
en
ts
/
py
s
R
at
e 
pe
r 
10
0 
py
s (
95
%
 C
I)
U
ni
v
a
ri
at
e
M
ul
tiv
a
ri
at
e
SH
R
95
%
 C
I
p 
va
lu
e
SH
R
95
%
 C
I
p 
va
lu
e
74
3
/
26
21
7
2.
83
 (2
.64
, 3
.05
)
Ye
a
r 
o
f A
RT
 In
iti
at
io
n
0.
59
5
0.
74
6
 
20
03
-2
00
5
67
/
45
31
1.
48
 (1
.16
, 1
.88
)
0.
74
(0.
57
, 0
.96
)
0.
02
3
0.
73
(0.
56
, 0
.95
)
0.
02
1
 
20
06
-2
00
9
39
6
/
12
73
4
3.
11
 (2
.82
, 3
.43
)
1.
00
1.
00
 
20
10
-2
01
3
28
0
/
89
52
3.
13
 (2
.78
, 3
.52
)
0.
90
(0.
77
, 1
.07
)
0.
23
1
0.
83
(0.
69
, 0
.99
)
0.
03
4
A
ge
 a
t A
RT
 in
iti
at
io
n 
(ye
a
rs
)
0.
00
5
0.
00
3
 
≤3
0
24
5
/
66
94
3.
66
 (3
.23
, 4
.15
)
1.
00
1.
00
 
31
-4
0
25
5
/
10
72
1
2.
38
 (2
.10
, 2
.69
)
0.
67
(0.
56
, 0
.80
)
<
0.
00
1
0.
67
(0.
56
, 0
.80
)
<
0.
00
1
 
41
-5
0
15
0
/
55
48
2.
70
 (2
.30
, 3
.17
)
0.
73
(0.
59
, 0
.91
)
0.
00
4
0.
72
(0.
58
, 0
.89
)
0.
00
2
 
51
+
93
/
32
54
2.
86
 (2
.33
, 3
.50
)
0.
71
(0.
55
, 0
.92
)
0.
00
8
0.
69
(0.
53
, 0
.90
)
0.
00
7
Se
x
 
M
al
e
50
3
/
18
14
7
2.
77
 (2
.54
, 3
.02
)
1.
00
1.
00
 
Fe
m
al
e
24
0
/
80
70
2.
97
 (2
.62
, 3
.38
)
1.
05
(0.
89
, 1
.25
)
0.
54
6
1.
13
(0.
94
, 1
.36
)
0.
18
6
M
od
e 
of
 H
IV
 E
xp
os
ur
e
<
0.
00
1
0.
00
5
 
H
et
er
os
ex
u
al
 c
on
ta
ct
50
3
/
18
13
9
2.
77
 (2
.54
, 3
.03
)
1.
00
1.
00
 
H
om
os
ex
u
al
 c
on
ta
ct
10
6
/
38
93
2.
72
 (2
.25
, 3
.29
)
1.
21
(0.
95
, 1
.54
)
0.
13
0
1.
36
(1.
05
, 1
.76
)
0.
02
1
 
In
jec
tin
g d
rug
 us
e
65
/
17
86
3.
64
 (2
.85
, 4
.64
)
1.
89
(1.
41
, 2
.55
)
<
0.
00
1
1.
65
(1.
19
, 2
.30
)
0.
00
3
 
O
th
er
/u
nk
no
w
n
69
/
24
00
2.
88
 (2
.27
, 3
.64
)
1.
16
(0.
89
, 1
.52
)
0.
26
9
1.
11
(0.
85
, 1
.44
)
0.
44
0
Ti
m
e-
up
da
te
d 
C
D
4 
(ce
lls
/μL
)
<
0.
00
1
<
0.
00
1
 
≤5
0
11
7
/
11
75
9.
96
 (8
.31
, 1
1.9
3)
1.
00
1.
00
 
51
-1
00
61
/
10
98
5.
56
 (4
.32
, 7
.14
)
0.
60
(0.
43
, 0
.82
)
0.
00
1
0.
59
(0.
43
, 0
.82
)
0.
00
1
 
10
1-
20
0
14
4
/
36
79
3.
91
 (3
.32
, 4
.61
)
0.
50
(0.
39
, 0
.65
)
<
0.
00
1
0.
48
(0.
37
, 0
.62
)
<
0.
00
1
 
20
1+
36
9
/
16
88
3
2.
19
 (1
.97
, 2
.42
)
0.
34
(0.
27
, 0
.44
)
<
0.
00
1
0.
32
(0.
25
, 0
.41
)
<
0.
00
1
 
N
ot
 te
ste
d
52
/
33
82
1.
54
 (1
.17
, 2
.02
)
0.
21
(0.
15
, 0
.30
)
<
0.
00
1
0.
19
(0.
14
, 0
.28
)
<
0.
00
1
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
De La Mata et al. Page 16
Ev
en
ts
/
py
s
R
at
e 
pe
r 
10
0 
py
s (
95
%
 C
I)
U
ni
v
a
ri
at
e
M
ul
tiv
a
ri
at
e
SH
R
95
%
 C
I
p 
va
lu
e
SH
R
95
%
 C
I
p 
va
lu
e
Ti
m
e-
up
da
te
d 
H
IV
 v
ir
al
 lo
ad
 (c
op
ies
/m
L)
 
≤1
00
00
0
17
7
/
85
00
2.
08
 (1
.80
, 2
.41
)
1.
00
1.
00
 
>
10
00
00
14
/
46
2
3.
03
 (1
.80
, 5
.12
)
0.
83
(0.
47
, 1
.48
)
0.
53
5
0.
58
(0.
32
, 1
.05
)
0.
07
2
 
N
ot
 te
ste
d
55
2
/
17
25
6
3.
20
 (2
.94
, 3
.48
)
0.
96
(0.
78
, 1
.18
)
0.
69
9
0.
84
(0.
67
, 1
.04
)
0.
11
4
Fi
rs
t A
RT
 re
gi
m
en
0.
33
3
0.
39
0
 
N
RT
I+
N
N
RT
I
70
0
/
23
87
9
2.
93
 (2
.72
, 3
.16
)
1.
00
1.
00
 
N
RT
I+
PI
41
/
21
27
1.
93
 (1
.42
, 2
.62
)
1.
01
(0.
70
, 1
.46
)
0.
96
5
1.
03
(0.
71
, 1
.49
)
0.
87
3
 
O
th
er
2
/
21
1
0.
95
 (0
.24
, 3
.8)
0.
36
(0.
09
, 1
.40
)
0.
14
0
0.
38
(0.
10
, 1
.55
)
0.
17
8
H
ep
at
iti
s B
 c
o-
in
fe
ct
io
n
0.
17
0
 
N
eg
at
iv
e
51
9
/
20
69
3
2.
51
 (2
.3,
 2.
73
)
1.
00
1.
00
 
Po
sit
iv
e
59
/
23
62
2.
50
 (1
.94
, 3
.22
)
1.
04
(0.
80
, 1
.37
)
0.
75
5
1.
01
(0.
77
, 1
.33
)
0.
93
6
 
N
ot
 te
ste
d
16
5
/
31
62
5.
22
 (4
.48
, 6
.08
)
1.
89
(1.
53
, 2
.34
)
<
0.
00
1
1.
43
(0.
99
, 2
.08
)
0.
06
0
H
ep
at
iti
s C
 co
-in
fe
ct
io
n
0.
00
2
 
N
eg
at
iv
e
49
9
/
20
47
2
2.
44
 (2
.23
, 2
.66
)
1.
00
1.
00
 
Po
sit
iv
e
73
/
23
64
3.
09
 (2
.46
, 3
.88
)
1.
79
(1.
39
, 2
.31
)
<
0.
00
1
1.
54
(1.
16
, 2
.05
)
0.
00
3
 
N
ot
 te
ste
d
17
1
/
33
82
5.
06
 (4
.35
, 5
.87
)
2.
00
(1.
62
, 2
.46
)
<
0.
00
1
1.
50
(1.
04
, 2
.18
)
0.
03
0
C
lin
ic
al
 S
ite
<
0.
00
1
<
0.
00
1
 
Ca
m
bo
di
a
32
3
/
97
06
3.
33
 (2
.98
, 3
.71
)
1.
00
1.
00
 
H
on
g 
K
o
n
g
14
/
31
10
0.
45
 (0
.27
, 0
.76
)
0.
14
(0.
08
, 0
.23
)
<
0.
00
1
0.
11
(0.
06
, 0
.20
)
<
0.
00
1
 
In
do
ne
sia
11
4
/
31
28
3.
64
 (3
.03
, 4
.38
)
1.
02
(0.
82
, 1
.27
)
0.
84
8
0.
53
(0.
40
, 0
.70
)
<
0.
00
1
 
Si
ng
ap
or
e
22
2
/
54
85
4.
05
 (3
.55
, 4
.62
)
1.
06
(0.
89
, 1
.27
)
0.
48
0
1.
00
(0.
78
, 1
.27
)
0.
97
5
 
Vi
et
na
m
 (S
ite
 1)
4
/
15
33
0.
26
 (0
.10
, 0
.70
)
0.
06
(0.
02
, 0
.15
)
<
0.
00
1
0.
04
(0.
01
, 0
.11
)
<
0.
00
1
 
Vi
et
na
m
 (S
ite
 2)
29
/
12
74
2.
28
 (1
.58
, 3
.28
)
0.
45
(0.
30
, 0
.66
)
<
0.
00
1
0.
29
(0.
18
, 0
.45
)
<
0.
00
1
 
So
ut
h 
Ko
re
a
37
/
19
80
1.
87
 (1
.35
, 2
.58
)
0.
64
(0.
45
, 0
.90
)
0.
00
9
0.
56
(0.
35
, 0
.89
)
0.
01
3
ˆ
G
lo
ba
l p
-v
al
ue
s a
re
 te
st 
fo
r l
in
ea
r t
re
nd
 w
hi
le
 a
ll 
ot
he
r g
lo
ba
l p
-v
al
ue
s a
re
 te
st 
fo
r h
et
er
og
en
ei
ty
.
N
ot
e 
th
at
 g
lo
ba
l p
-v
al
ue
 te
st 
w
as
 n
o
t c
on
du
ct
ed
 if
 th
er
e 
w
er
e 
on
ly
 tw
o
 c
at
eg
or
ie
s w
he
n 
us
in
g 
te
st 
fo
r h
et
er
og
en
ei
ty
 o
r t
hr
ee
 c
at
eg
or
ie
s w
he
re
 o
ne
 w
as
 ‘
N
ot
 te
ste
d’
 w
he
n 
us
in
g 
te
st 
fo
r l
in
ea
r t
re
nd
.
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
De La Mata et al. Page 17
1 M
ul
tiv
ar
ia
te
 m
od
el
 w
as
 a
dju
ste
d f
or 
ye
ar 
of 
AR
T 
in
iti
at
io
n,
 a
ge
 a
t A
RT
 in
iti
at
io
n,
 se
x
, 
m
o
de
 o
f H
IV
 ex
po
su
re
, t
im
e-
up
da
te
d 
CD
4 
co
un
t, 
tim
e-
up
da
te
d 
H
IV
 v
ira
l l
oa
d,
 fi
rs
t A
RT
 re
gi
m
en
, h
ep
at
iti
s B
 c
o-
in
fe
ct
io
n,
 h
ep
at
iti
s C
 c
o-
in
fe
ct
io
n 
an
d 
cl
in
ic
al
 si
te
.
2 N
RT
I =
 n
uc
le
os
id
e 
re
v
er
se
 tr
an
sc
rip
ta
se
 in
hi
bi
to
r.
3 N
N
RT
I =
 n
on
nu
cl
eo
sid
e 
re
v
er
se
 tr
an
sc
rip
ta
se
 in
hi
bi
to
r.
4 P
I =
 p
ro
te
as
e 
in
hi
bi
to
r.
5 I
nc
lu
de
s a
ll 
ot
he
r a
nt
ire
tro
v
ira
l d
ru
g 
re
gi
m
en
 c
om
bi
na
tio
ns
.
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 April 15.
